Financing Obligations - Schedule of Effective Interest Rate Drawdown after Taking into Consideration Beneficial Ownership Features and Right to Borrow Asset Discount (Detail) - USD ($)	3 Months Ended				12 Months Ended
	Jun. 30, 2014	Mar. 31, 2014	Dec. 31, 2013	Sep. 30, 2013	Dec. 31, 2015	Dec. 31, 2014	Dec. 31, 2013
Debt Instrument [Line Items]
Draw Amount					$ 2,914,000	$ 50,830,000	$ 15,000,000
Beneficial Conversion Feature			$ 3,112,000			1,032,000	3,112,000
Teva Pharmaceuticals USA, Inc. [Member]
Debt Instrument [Line Items]
Draw Amount	$ 5,000,000	$ 5,000,000	5,000,000	$ 10,000,000		$ 25,000,000
Beneficial Conversion Feature	148,000	883,000	657,000	2,455,000			657,000
Reclassified Unamortized Right-to-Borrow	$ 252,000	$ 318,000	$ 393,000	$ 900,000			$ 393,000
Debt instrument, effective interest rate	6.60%	11.60%	10.20%	14.20%			10.20%